Adverse effects of inhalational corticosteroids in oral cavity: Role of attending physician and periodontist

Singh R, Khanna A, Batta A, Platia S, Parihar AS, Bhatia RS

Singh R, Khanna A, Batta A, Platia S, Parihar AS, Bhatia RS

Keywords: inhalational corticosteroids, oral health, adverse drug reaction, oral candidiasis, xerostomia, gingivitis

Abstract

Abstract: Inhaled corticosteroids forms the corner stone of treatment in airflow obstructive disorders such as asthma, small airway disease and even COPD. Asthma is a serious global
health problem that usually starts in childhood and many a times, the patient has to take inhaled therapy lifelong. On the contrary, COPD usually starts in later years and many patients
with severe airway obstruction have to take high dose of inhaled therapy for long duration. Use of high dosage and for long duration of inhalational corticosteroid therapy being the
mainstay treatment along with other medicines, is likely to exhibit several adverse effects on the oral tissues. Since the major proportion of the inhaled drug is retained in the oral cavity
and oropharynx, it is likely to interfere in the normal physiology of oral tissues. This article will review the influence of inhaled corticosteroids on the oral health including gingiva and
teeth. It is suggested that timely interaction between periodontist and attending physician can improve safety profile of the patient.

References

1. Bhatia R S. Rising trends in respiratory diseases and their prevention. IN: Medicine Update, API; Ed, Sidharata Das. 2003; 13:260-67.
2. Bhatia R S. Respiratory disease pattern at a private clinic in Ludhiana, Punjab. Lung India. 1995;13:125-26.
3. R S Bhatia, Surya Kant. Bronchial Asthma, PeePee Publishers New Delhi 2008.
4. Bhatia R S, Singhal M. Acute severe asthma – management. Medicine Update. 1999;6: 783-84
5. Bhatia R S. Low dose theophylline in asthma: let us give a chance. JAPI. 2003;51:53-54.
6. Barnes PJ. How corticosteroids control inflammation. Br J Pharmacol. 2006;148:245–254.
7. R S Bhatia, Surya Kant. COPD, PeePee Publishers New Delhi 2014.
8. Ryberg M, Moller C, Ericson T. Saliva composition and caries development in asthmatic patients treated with beta-2 adrenoceptor agonists: A 4-year follow-up study. Scand J Dent Res. 1991;99:212-8.
9. Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J et al. Local side-effects of inhaled corticosteroids in asthmatic children: Influence of drug, dose, age, and device. Allergy. 2001;56:944-8.
10. Godara N, Godara R, Khullar M. Impact of inhalation therapy on oral health. Lung India. 2011;28:272-5.
11. Tootla R, Toumba KJ, Duggal MS. An evaluation of the acidogenic potential of asthma inhalers. Arch Oral Biol. 2004;49:275-83.
12. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-24.
13. Torres SR, Peixoto CB, Caldas DM, Silva EB, Akiti T, Nucci M et al. Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 93:149-54.
14. Regezi JA, Sciubba JJ, Jordan RC. Salivary Gland Diseases. In: Regezi JA, Sciubba JJ, Jordan RC, editors. Oral Pathology, Clinical Pathologic Correlations, 5th ed. St. Louis: Saunders; 2008. p. 191-2.
15. De Rossi SS et al. Oral ulcerations in patients with severe asthma; J Amer Dent Assoc. 2010;141:47-51.
16. Kreiner B, Bennett JD. Drugs acting on the respiratory system. In: Yagiela JA, Neidle EA, Dowd FJ, editors. Pharmacology and therapeutics for dentistry, 5th ed. St. Louis: Mosby; 2004.
p. 536.
17. Porter SR, Scully C; Oral malodour (halitosis); BMJ. 2006;333:632-35.
18. Sivasithamparam K, Young WG, Jirattanasopa V et al. Dental erosion in asthma: a case-control study from southeast Queensland. Aust Dent J. 2002;47:298–303.
19. Dugmore CR, Rock WP. Asthma and tooth erosion. Is there an association? Int J Paediatr Dent. 2003;13:417–424.
20. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004;15:221-39.
21. O’Sullivan EA, Curzon ME. Drug treatments for asthma may cause erosive tooth damage. BMJ. 1998;317:820.
22. Roland JN, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213–219.
23. Kurt E, Yildirim H, Kiraz N et al. Oropharyngeal candidiasis with dry-powdered fluticasone propionate: 500 microg ⁄ day versus 200 microg ⁄ day. Allergol Immunopathol. 2008;
36:17–20.
24. Ersin NK, Gu¨ len F, Eronat N et al. Oral and dental manifestations of young asthmatics related to medication, severity and duration of condition. Pediatr Int. 2006;48:549–554.
25. Walker GD, Cai F, Shen P, Adams GG, Reynolds C, Reynolds EC. Casein phosphopeptide-amorphous calcium phosphate incorporated into sugar confections inhibits the progression
of enamel subsurface lesions in situ. Caries Res. 2010;44:33-40.
26. R S Bhatia, G K Sidhu. Diabetes mellitus & respiratory system, IN: Selected Topics in Diabetes Mellitus, PeePee Publishers New Delhi 2007.
27. Kaufman E, Lamster IB. Analysis of saliva for periodontal diagnosis: A review. J Clin Periodontol. 2000; 27:453-65.
28. Hyyppa T. Gingival IgE and histamine concentrations in patients with asthma and in patients with periodontitis. J Clin Periodontol. 1984;11:132–137.
29. McDerra EJ, Pollard MA, Curzon ME. The dental status of asthmatic British school children. Pediatr Dent. 1998;20:281– 287.
30. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995;96:571–579.
31. Wactawski-Wende J. Periodontal diseases & osteoporosis: association and mechanisms. Ann Periodontol. 2001;6:197– 208.